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THE NEXT GENERATION OF THERAPEUTICS FACE DRAMATIC CHALLENGES - IS ICB AN ANSWER? 
 




Integrated and continuous manufacturing strategies take evolving forms, but are driven by similar needs: the 
ability to meet the market demand, cost reduction, and speed to patient.  For example, Amgen’s next-generation 
Manufacturing is reported to achieve a smaller facility footprint with intensification of processes and the use of 
certain disposable systems.  Sanofi, Shire, Jansen publically report applying various extents of continuous and 
integrated processes.  Novartis is currently commercializing its Advanced Integrated Biomanufacturing platform 
as an end-to-end manufacturing aimed at capacity, speed, cost, and patient access. 
 
While CHO-derived products represent a major component of the current industry portfolio, there are 
opportunities to utilize integrated and/or continuous techniques to drive benefits beyond productivity.  In the 
case of microbial processes, continuous fermentation approaches may be able to drive quality attributes that are 
elusive in batch systems.  Other emerging aspects of the industry, such as cell or gene therapy, are in the 
phase where meeting demand is the priority and driver.  For these emerging therapeutic areas, integrated 
processing will likely be necessary to break through to the “cost effective” and/or “fast” stage.  While we should 
not expect to see a direct carry-over of the end-to-end integrated process, that are developed for large proteins, 
key technology features will certainly be leveraged.  We will advance the discussion around the current focus 
areas and future possibilities. 
 
